Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects

Table 3 Reduction in body weight in Meratrim and placebo groups over 16 week study period

Parameter Reduction	Weeks	Placebo	Meratrim	Net reduction^a,b	P value
Parameter Reduction	Weeks	(n = 28)	(n = 29)	Net reduction^a,b	P value
Body weight (kg)	2	0.42 ± 0.18	0.51 ± 0.16	0.09 (0.1 %)	0.749
	4	0.64 ± 0.29	1.53 ± 0.20	0.89 (1.2 %)	0.048*
	8	1.26 ± 0.40	2.10 ± 0.25	0.84 (1.1 %)	0.190
	12	1.19 ± 0.43	3.14 ± 0.28	1.95 (2.6 %)	0.002*
	16	1.10 ± 0.46	5.09 ± 0.38	3.99 (5.3 %)	<0.0001*

Values represent mean ± SE
*Significant difference between Meratrim and placebo group mean values calculated using ANCOVA with baseline as covariate
^aNet reduction = Meratrim minus placebo
^bNumbers in parenthesis represents the % net reduction from baseline for Meratrim group